Pinealon — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Pinealon

Also known as: EDR peptide, Glu-Asp-Arg, T-33, EDR tripeptide

Short regulatory tripeptide / peptide bioregulator (cytogen)

Research chemicalLast updated: October 19, 2026Based on 21 peer-reviewed studies

What it is

Pinealon is a short peptide studied in animal models for cognitive protection, hypoxia resistance, and anti-aging effects, particularly in the brain. It is thought to work by entering cell nuclei and influencing gene expression. No FDA-approved use; primarily studied in Russian research with limited independent replication.

The scientific side

Pinealon (Glu-Asp-Arg) is a synthetic tripeptide that has been shown to penetrate into animal cell nuclei, where it may interact with DNA and histone proteins, binding preferentially to CNG and CAG nucleotide sequences and influencing gene expression epigenetically. In the context of Alzheimer's disease pathogenesis, the EDR peptide is proposed to modulate the MAPK/ERK signaling pathway and influence synthesis of proapoptotic proteins (caspase-3, p53), antioxidant enzymes (SOD2, GPX1), and transcription factors including PPARA and PPARG. Pinealon restricts reactive oxygen species (ROS) accumulation in a dose-dependent manner in cerebellar granule cells, neutrophils, and PC12 cells, and modulates the cell cycle via delayed ERK 1/2 activation. It stimulates serotonin expression in aging brain cortex cultures, with molecular docking indicating complementarity to the CCTGCC nucleotide sequence in the tryptophan hydroxylase gene. In hypoxia models, pinealon promotes neurogenesis and reduces neuroinflammatory reactions, and stimulates antioxidative enzyme systems rather than directly scavenging ROS (PMID 25051764, PMID 18546825). Short peptides including pinealon can interact with the major groove of DNA, affecting guanine N7 and O6 atoms.

Class: Short regulatory tripeptide / peptide bioregulator (cytogen)

Administration & storage

Administration
Intraperitoneal injection (PMID: 21809624)
Storage
No storage conditions for pinealon are described in the reviewed abstracts.
Cautions
Prooxidant activity was detected by chemiluminescence in a human study of patients taking pinealon.,Pinealon increased caspase-3 activity moderately in false-operated (sham surgery) animals, suggesting possible context-dependent effects on apoptotic signaling.,In vitro data show that pinealon elevates the stationary level of intracellular reactive oxygen species while simultaneously decreasing cell death, indicating complex and not fully understood redox effects.,No clinical trial safety data are available; the reviewed literature lacks formal human pharmacokinetic, pharmacodynamic, or toxicology studies.,Sterile technique is essential for any injectable preparation; however, no injectable human protocols for pinealon were identified in the reviewed literature.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification

WADA

Not stated in reviewed literature — requires manual verification

Health Canada

Not stated in reviewed literature — requires manual verification